News | Advanced Visualization | November 21, 2016

Arterys Showcases FDA-cleared 4D Flow MRI Software at RSNA 2016

Software for advanced visualization of 4-D cardiac flow, volumetry and function to be displayed at GE Healthcare booth

Arterys, 4-D Flow software, cardiac MRI, RSNA 2016

November 21, 2016 — Arterys will showcase its recently U.S. Food and Drug Administration (FDA) 510(k)-cleared Arterys Software platform at the upcoming Radiological Society of North America (RSNA) 2016 meeting, Nov. 27-Dec. 1 in Chicago. The company will also present new data on cardiac clinical applications using the Arterys 4-D Flow software during the RSNA poster sessions.

Arterys received 510(k) clearance from the FDA for its Arterys Software earlier this month, paving the way for use in clinical settings for the quantification of cardiac flow. This includes 4-D Flow and 2-D Phase Contrast workflows, and cardiac function measurements. Arterys plans on launching the product in the United States through a partnership with GE Healthcare's ViosWorks product.

Arterys representatives will be on hand at the GE Healthcare booth to help demonstrate how the product integrates with ViosWorks to provide comprehensive visualization and quantification of the cardiac anatomy, function and flow. Powered by the Arterys software, ViosWorks will be the first clinically available cardiovascular solution that delivers cloud-based, real-time processing of images with resolutions previously unattainable, according to the company.

Arterys will also host three expert sessions in the Quantitative Imaging Reading Room to provide 4-D Flow magnetic resonance imaging (MRI) software demonstrations on applications of cardiac flow 4-D MRI, and cardiac volumetry and function features. Arterys medical experts will also discuss how deep learning can be applied to automate measurements and provide accurate and consistent cardiac flow and function.

For more information: www.arterys.com

Related Content

National Imaging Solutions, a recognized leader in medical imaging and radiology solutions, announced it has acquired DynaRad — the oldest manufacturer of portable X-ray systems in the US. This new investment will allow National Imaging Solutions to support its customers by supplying them with DynaRad portable X-ray machines, including a mobile field X-ray device using nanotube technology.
News | Radiology Business | May 11, 2021
May 11, 2021 — ...
New Module Creates a Warped MRI Scan that Matches Real-Time Ultrasound Results (Graphic: Business Wire)

New Module Creates a Warped MRI Scan that Matches Real-Time Ultrasound Results (Graphic: Business Wire)

News | Artificial Intelligence | May 07, 2021
3D aMRI not only provides a stunning look inside the "beating brain", but it can also measure this physiological motion in all directions. Here, the amplitude of brain motion is overlayed for each brain slice and orientation in 3D. Image credit: 3D aMRI method outlined in Abderezaei et al. Brain Multiphysics (2021); Terem et al. Magnetic Resonance in Medicine (2021).

3D aMRI not only provides a stunning look inside the "beating brain", but it can also measure this physiological motion in all directions. Here, the amplitude of brain motion is overlayed for each brain slice and orientation in 3D. Image credit: 3D aMRI method outlined in Abderezaei et al. Brain Multiphysics (2021); Terem et al. Magnetic Resonance in Medicine (2021).

News | Magnetic Resonance Imaging (MRI) | May 06, 2021
May 6, 2021 — Magnetic Resonance Imaging
After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.

News | PET Imaging | May 05, 2021
May 5, 2021 — For patients with brain metastases, amino acid ...
News | Artificial Intelligence | April 30, 2021
April 30, 2021 — Canon Medical is bringing the power of accessible...
The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

News | Cardiac Imaging | April 30, 2021
April 30, 2021 — In almost 10 percent of...